Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Esslingen Am Neckar – page 22

1 006 clinical trials in Esslingen Am Neckar, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Esslingen Am Neckar at a glance
1 006
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 006 trials in Esslingen Am Neckar

Open in trial search

Study on Venetoclax, Obinutuzumab, and Pirtobrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:University Of Cologne

Study Comparing Treosulfan and Melphalan with Fludarabine for Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Undergoing Transplantation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fludarabine
  • Sponsor:Technische Universitat Dresden

Study on Revumenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Bladder cancer

Recruiting

Study of EG-70 for Patients with Non-Muscle Invasive Bladder Cancer Unresponsive to BCG or High-Risk Patients New to BCG or with Incomplete BCG Treatment

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lauromacrogol 400
  • Sponsor:Engene Inc.

Study of TCR-Modified T Cell Therapy with ANOC-001, ANOC-002, and ANOC-003 for Adults with Advanced Pancreatic Cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ANOC-001
  • Sponsor:Anocca AB

Breast cancer+1

Recruiting

A Study of Trastuzumab Deruxtecan Treatment for Patients with Early-Stage HER2-Positive or HER2-Low Breast Cancer Who Show Signs of Molecular Relapse

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Universitaetsklinikum Ulm AöR

Evaluation of Cemiplimab Safety and Effectiveness as First Treatment for Advanced Basal Cell Carcinoma in Adult Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Study of durvalumab with chemotherapy (paclitaxel, cisplatin, carboplatin, vinorelbine) in patients with stage IIIA/B non-small cell lung cancer that can be removed by surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Rheinische Friedrich-Wilhelms-Universitaet Bonn

Study on Reducing Acute Kidney Injury After Heart Surgery Using Angiotensin II or Noradrenaline for Patients with Low Blood Pressure

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Angiotensin II
  • Sponsor:Universitaet Muenster

Study Comparing BMS-986489 with Chemotherapy to Atezolizumab with Chemotherapy for First-Line Treatment in Patients with Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Vulval cancer

Recruiting

Study of Pembrolizumab and Lenvatinib for Patients with Advanced Vulvar Cancer Not Suitable for Surgery or Radiotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:AGO Research GmbH

Study of DNAJB1-PRKACA Peptide Vaccine for Patients with Fibrolamellar Hepatocellular Carcinoma and Other Tumors with Oncogenic Driver Fusion

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:DNAJB1-PRKACA TRIFLUORACETATE
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Esslingen Am Neckar

What the registry says about research in the country

01 Lung Cancer Research

Extensive studies focusing on non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), evaluating novel treatment combinations and targeted therapies for various disease stages.

  • Advanced and metastatic disease management
  • Post-surgical treatment optimization
  • Combination therapy approaches

Multiple trials investigating immunotherapy combinations and targeted treatments for improved patient outcomes.

02 Breast Cancer Studies

Innovative research targeting hormone receptor-positive and triple-negative breast cancer, exploring new therapeutic strategies and treatment combinations.

  • Early-stage disease management
  • HER2-negative breast cancer
  • Perioperative treatment approaches

Focus on developing personalized treatment strategies and improving survival outcomes.

03 Hematologic Malignancies

Groundbreaking studies in chronic lymphocytic leukemia (CLL) and related blood cancers, evaluating novel drug combinations and treatment duration strategies.

  • Treatment optimization
  • Disease monitoring approaches
  • Targeted therapy combinations

Research aimed at improving treatment responses and patient quality of life.

04 Gastrointestinal Cancers

Research focusing on hepatocellular carcinoma and gastric cancer, investigating innovative combination therapies and surgical approaches.

  • Advanced disease treatment
  • Perioperative therapy
  • Immunotherapy applications

Studies evaluating novel treatment strategies for improved patient outcomes.

05 Gynecologic Oncology

Clinical trials in ovarian cancer and related conditions, studying maintenance therapies and combination treatments for advanced disease.

  • First-line treatment strategies
  • Maintenance therapy optimization
  • Targeted treatment approaches

Focus on improving survival rates and treatment effectiveness.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.